Desmopressin Acetate 0.2 mg Tablets, Fasting

Summary

The objective of this study was to compare the single-dose relative bioavailability of TEVA and Aventis Pharmaceuticals (DDAVP®) 0.2 mg desmopressin acetate tablets following a 0.8 mg dose under fasting conditions.

Timeline

Start

2003-07

Primary completion

2003-08

Completion

2003-08

Outcome

Met primary endpoint

registry Test/Ref Ratio of LS Means x 100 97.5 (90% CI 87.8 to 108.3) NCT00835211 ↗

registry Test/Ref Ratio of LS Means x 100 95.6 (90% CI 86.9 to 105.2) NCT00835211 ↗

registry Test/Ref Ratio of LS Means x 100 96.5 (90% CI 87.7 to 106.1) NCT00835211 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desmopressin	Peptide	0.8 mg	—

Indications

No indication recorded.